WuXi XDC and Phamadule Morimatsu Achieve Milestone with Successful Shipment of ADC Modular Facilities for Singapore Manufacturing Site

by ocean.zhang@egplusww.com | Oct 16, 2024 | News & Resources - Press Releases, press-releases

Shanghai, China, October 14, 2024 – In the global biopharmaceutical industry, the innovation and production of antibody-drug conjugates (ADCs) and other bioconjugates(XDCs) are increasingly recognized as critical drivers of industry growth, offering transformative...

WuXi XDC Honored on Fortune China’s 2024 TECH 50 List

by noah.shi@egplusww.com | Aug 28, 2024 | News & Resources - Press Releases, press-releases

On August 21, 2024, Fortune announced its inaugural “2024 Fortune China Technology 50” list. Recognizing WuXi XDC (Stock Code: 2268.HK), a global leader in end-to-end CRDMO services focused on Antibody-Drug Conjugates (ADCs) and other bioconjugates, for...

WuXi XDC Reports Strong Business Updates with Superior Financial Results in 1H 2024: Poised for Future Growth

by ocean.zhang@egplusww.com | Aug 20, 2024 | News & Resources - Press Releases, press-releases

Revenue surged by 67.6% YoY to RMB 1,665 million Gross profit surged by 133.4% to RMB 535 million, with a gross profit margin of 32.1%, a 9.0 percentage points increase compared to 1H 2023. Net profit increased by 175.5% to RMB 488 million, with a net profit margin of...

A Complex Play: The Essential Role of CMC in ADC Drug Development

by gavin guo | Aug 1, 2024 | News & Resources - Press Releases, press-releases

Leon: Fantastic! Now I think everyone in the audience and around the world understands why we’ve invited three experts who definitely have many decades of experience in their respective fields, so let’s dive into it today. First, we will talk about how CMC...

WuXi XDC Releases Inaugural ESG Report
Demonstrating Leadership in Sustainability and Innovation

by noah.shi@egplusww.com | May 29, 2024 | News & Resources - Press Releases, press-releases

SHANGHAI, May 29, 2024—WuXi XDC, a leading Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in antibody-drug conjugates (ADCs) and broader bioconjugates, announced the publication of its inaugural Environmental, Social, and...

WuXi XDC Delivers Outstanding Performance in 2023 with over 110% Year-On-Year Growth for Both Revenue and Adjusted Net Profit and Achieves Significant Corporate Milestones

by helen han | Mar 25, 2024 | News & Resources - Press Releases, press-releases

Revenue reached RMB 2,124 million, an increase of 114% compared with Year 2022 Adjusted net profit reached RMB 412 million, an increase of 112% compared with Year 2022 Total number of integrated projects increased to 143 50 new integrated projects signed in 2023...

« Older Entries